Cure8 news brief
This article reports an investigational stem cell therapy (StemSmart MSCs) showing safety and clinical responses in a small group of patients with fistulising Crohn’s disease — a serious complication that’s often hard to treat.
Early positive signals could lead to larger trials and a potential new option for perianal fistulas if results hold up.
Patients with perianal or fistulising Crohn’s disease, caregivers, gastroenterologists and colorectal surgeons, and researchers focused on stem-cell or regenerative therapies for IBD.
NeuroScientific Biopharmaceuticals reports positive outcomes from a Special Access Scheme (real-world) trial of its StemSmart mesenchymal stem cell (MSC) therapy in five patients with fistulising Crohn’s disease. Four of five patients met the company’s clinical response criteria for fistula improvement; the fifth had a partial response.
No serious adverse events were reported. MRI showed trends toward fistula healing but was considered early to show closure; several patients had setons removed. The company plans a Phase 2 trial to study dosing frequency/timing and MRI assessments.
These results come from a very small, uncontrolled Special Access cohort (five patients) and were reported by the company. They provide early signals about safety and possible efficacy in difficult-to-treat perianal fistulas but do not establish definitive benefit.
Larger, controlled trials will be needed to confirm results and define risks, dosing, and how this compares with existing therapies. If you have fistulising Crohn’s disease or follow research in stem cell therapies for IBD, this is a preliminary development worth watching.
The company’s next planned Phase 2 trial and peer-reviewed publication would provide more rigorous data.
Results are from five patients treated under Australia’s Special Access Scheme and were reported by the company; this is early, uncontrolled data. The company plans a Phase 2 trial to study dosing and MRI endpoints. Wait for larger, controlled studies and peer-reviewed publication before drawing conclusions about safety or effectiveness.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This trial shows darvadstrocel did not outperform placebo for complex perianal Crohn’s fistulas, so it does not support changing care now. High healing rates after surgical curettage and closure suggest the surgical step...
This article reports the start of a first-in-human trial testing extracellular vesicles as a new regenerative treatment for complex perianal fistulas in Crohn's disease, a hard-to-treat complication with limited options.
This is an early positive interim report of a new oral drug (ALK5 inhibitor) aimed at fibrostenosing Crohn’s disease. Treatments that target intestinal strictures are an important area of research for people with...
